Delveinsight

SEPTEMBER 23, 2021

Boehringer stated that the Abexxa’s generation aims at cancer-specific proteins situated throughout the mobile versus proteins at the mobile membrane broadening the selection of possible cancer antigen objectives. The biotech has evolved a T-cell receptor-like antibody to damage a selected immune checkpoint in oncology.

RNA 61

RNA Gene Therapy Gene Protein 61

Roots Analysis

AUGUST 15, 2023

Biomanufacturing utilizing cell free systems is an emerging area of research that enables the synthesis of different biomolecules, such as cytotoxic proteins, fusion proteins, post translationally modified proteins, antibodies, enzymes, vaccines and other complex proteins, without the use of living cells.

Protein 52

Protein In-Vitro Production Reagent 52

pharmaphorum

JANUARY 5, 2022

The new vaccine differs from the currently approved shots because it delivers antigens for both the spike protein and other proteins found in SARS-CoV-2. That could mean it is less susceptible to the loss of efficacy to vaccines that can occur when there are changes in the spoke protein – as witnessed with the new Omicron variant.

Protein 122

Protein Vaccination Vaccine Immune Response 122

Pharmaceutical Technology

DECEMBER 9, 2022

M&A – Commended PRODUCT LAUNCHES – Commended RESEARCH AND DEVELOPMENT – Commende d. Solvias is a Swiss-based pharmaceutical company focused on contract research, development and manufacturing. Pharmaceutical Technology Excellence Rankings – The Verdict.

Development 130

Development Manufacturing Production Vaccination 130

Pharmaceutical Technology

FEBRUARY 14, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin 1, which are now well established in the industry.

In-Vivo 130

In-Vivo DNA Antibody Gene 130

Drug Discovery World

AUGUST 4, 2023

The pace of innovation in cancer drug discovery showed no signs of slowing this week, with several pretty momentous discoveries boosting research in the sector. News round-up for 31 July – 4 August by DDW Digital Content Editor Diana Spencer.

Drugs 52

Drugs RNA Gene Scientist 52

Delveinsight

AUGUST 26, 2021

Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks. This system is designed to deliver RNA editing technology or other payloads directly to particular body areas, such as the nervous system or muscle. and Leila Zegna, director of the Kabuki Syndrome Foundation.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

The Pharma Data

JANUARY 20, 2021

based Gritstone Oncology is developing a novel COVID-19 vaccine based on adenovirus and messenger-RNA technology designed to combat future variants of the coronavirus. Emeryville, Calif.-based

Vaccination 52

Vaccination Vaccine RNA Protein 52

Pharmaceutical Technology

JUNE 4, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Genetics 130

Genetics Gene Expression DNA Antibody 130

Drug Discovery World

APRIL 6, 2023

Ahead of attending the American Association for Cancer Research (AACR) annual meeting from 14-19 April, 2023 at the Orange County Convention Center in Orlando, Florida, DDW’s Megan Thomas outlines what to expect from the event. Programme highlights The topic tracks include everything from clinical trials, drug development, immunology and bioinformatics, (..)

Protein 52

Protein Clinical Trials Clinical Trials Antibody 52

pharmaphorum

AUGUST 18, 2020

The consortium aims to rapidly develop drugs to fight SARS-CoV-2 and find virus neutralising antibodies. The trick is to look for proteins that are used across all coronavirus types and tend not to vary much from one virus species to another. But also included in the 77.7

Protein 106

Protein Pharma Companies RNA Drugs 106

The Pharma Data

MARCH 8, 2022

Researchers led by Prof. The virus carries the information to produce a series of proteins, capable of inhibiting antiviral recognition systems of the infected cell. Actually, these systems could identify viral genetic material (here: Ribonucleic acids/RNAs) and sound the alarm. Camouflage protects virus from immune system.

Immune Response 52

Immune Response RNA Protein Genetics 52

pharmaphorum

OCTOBER 16, 2020

Sanofi will shortly start human trials of a second coronavirus vaccine, developed with US biotech Translate Bio, after reporting that it stimulated antibodies against SARS-CoV-2 in preclinical testing. It started human testing of a protein subunit vaccine with partner GlaxoSmithKline last month. Chinese inactivated vaccine safe.

Trials 96

Trials Vaccination Vaccine Antibody 96

The Pharma Data

JANUARY 31, 2021

Both vaccines induced high levels of neutralizing antibodies comparable to or exceeding levels in human convalescent sera as well as a strong Th1-biased cell-mediated immunity. Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

pharmaphorum

NOVEMBER 17, 2020

There are 11 potential COVID vaccines in late-stage clinical development and since Pfizer’s announcement two more groups from Russia’s Gamaleya Research Institute and US biotech Moderna have published favourable efficacy results. Both Pfizer and Moderna vaccines use synthetic messenger RNA to activate the immune system against the virus.

Vaccination 66

Vaccination Vaccine RNA Clinical Trials 66

The Pharma Data

DECEMBER 3, 2020

S-Trimer adjuvanted with GSK’s pandemic adjuvant system induced neutralizing antibody titers (seroconversion) in 100% of participants at the selected 9 µg S-Trimer dose in both adult and elderly groups, with geometric mean titers (GMT) greater than 1:1,800. S-Trimer is intended to be adjuvanted. About Trimer-Tag © Technology.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. Preclinical data showed that two immunizations of the mRNA vaccine induced high neutralizing antibody levels that are comparable to the upper range of those observed in infected humans.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccination Vaccine Development 40

Delveinsight

JULY 29, 2021

billion in biobucks on the table to buy Teneobio and its suite of bispecific and multispecific antibody technologies focused on cancer and other disease targets. executive vice president of research and development at Amgen. Amgen has penned a major new buyout deal to boost its oncology pipeline further. Reese, M.D.,

Drugs 98

Drugs Protein Life Science Trials 98

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

pharmaphorum

SEPTEMBER 22, 2022

When exposed to a virus, one’s immune system develops antibodies in response to foreign antigens, with or without a vaccine. One arm of the immune system triggers antibodies, and the other triggers T-cells. Antibodies cover the pathogen of the virus and neutralise it. “On this front, the antibody works very well.

Vaccination 89

Vaccination Vaccine Antibody Clinical Trials 89

XTalks

NOVEMBER 30, 2023

Over the last 35 years, substantial strides have been made in tackling HIV/AIDS, propelled by advancements in medical research, enhanced accessibility to treatment and prevention and a more comprehensive understanding of the virus. World AIDS Day offers an occasion for reflection on the strides achieved thus far. percent in the placebo group.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

The Pharma Data

JULY 6, 2021

But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. Half of the recovered COVID-19 patients studied had T cell responses to highly networked epitopes identified by the research team.

Vaccination 52

Vaccination Vaccine Research Immune Response 52

Drug Discovery World

OCTOBER 16, 2023

Here, DDW’s Megan Thomas highlights the research taking place and where this is happening. This environment of research excellence, in turn, fosters R&D, innovation, spin-offs, start-ups, networking, collaboration and entrepreneurship, which sets a sturdy foundation that attracts funding, and creates an appealing work culture.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif. and CHENGDU, China , Feb.

Vaccination 52

Vaccination Vaccine Trials Protein 52

The Pharma Data

JULY 6, 2021

New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented. Sanofi highlights scientific innovations in the field of rare blood disorders at I STH 2021. ePoster Abstract # OC48.2 Oral Presentation.

Protein 52

Protein RNA Marketing Development 52

Find Me Cure

OCTOBER 13, 2019

This Breast Cancer Awareness Month we’d like to talk about emerging areas in metastatic breast cancer treatment since clinical research has come so far in recent years. HER2 is a protein that plays an important role in cancer cell growth and is found on the surface of cancer cells in a very high quantity in about 10-20% of breast cancers.

Development 52

Development DNA Clinical Trials Clinical Trials 52

pharmaphorum

JANUARY 17, 2023

Research into mRNA dates back to the 1970s, but with the approval of both Moderna and BioNTech/Pfizer’s vaccines, this approach has finally been validated. As it stands, mRNA vaccines and therapeutics can only provide benefits if they can reach the living cells and be processed into protein.

Vaccination 89

Vaccination Vaccine In-Vivo In-Vitro 89

Delveinsight

AUGUST 6, 2020

Transthyretin (TTR) is a protein that the liver produces to facilitate the transfer of thyroid hormone and vitamin A in the blood. However, due to specific reasons, the TTR protein begins to misfold and aggregate as fibrils, a process known as amyloidosis of Transthyretin (ATTR). Liver Transplantation.

Gene Silencing 52

Gene Silencing Protein Marketing Gene 52

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.

RNA 40

RNA Protein Genetics Gene Expression 40

The Pharma Data

AUGUST 3, 2021

As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio (NASDAQ: TBIO), a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00

Vaccination 52

Vaccination Vaccine Development Clinical Trials 52

pharmaphorum

DECEMBER 21, 2020

Their technology is based on synthetic messenger RNA – short for ribose nucleic acid – which is a short transcript of a longer DNA code. As it’s just a messenger molecule, it does not affect the body’s own genetic code when it is injected as a vaccine – but what it does do is instruct cells to code for copies of a certain protein.

Vaccination 90

Vaccination Vaccine Doctors Doctor 90

Drug Discovery World

AUGUST 3, 2022

Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. Over the years, a range of different CPPs have been developed, including natural translocating proteins through to newly-designed computer-prediction sequences 3.

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

The Pharma Data

DECEMBER 2, 2020

She is currently the CEO of Twentyeight-Seven, a biotech company focused on novel RNA biology that she co-founded alongside prominent Harvard investigators. Lisa is a senior pharmaceutical executive with more than 20 years of experience in research and drug discovery. She is also a Board member of the Sandford Burnham Prebys Institute.

Development 52

Development RNA Research Drugs 52

Pharmaceutical Technology

MAY 8, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

RNA 240

RNA Genetics Vaccination Vaccine 240

The Pharma Data

SEPTEMBER 1, 2020

with whom Roche has a global distribution agreement and had also launched a Rapid Antibody Test in July. About antigen testing An antigen test detects proteins which are structural or functional components of a pathogen and are thus very specific to that pathogen. The launch is a partnership with SD Biosensor Inc.,

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52